

Press
RELEASE
Read and download the financial news from NFL Biosciences. To receive our announcements directly in your mailbox subscribe to our mailing list.
-
September, 25, 2023 • Promising results of the PRECESTO clinical trial revealing a prolonged effect for NFL-101 and modification of the strategy for communicating the CESTO II study results
-
July, 05, 2023 • Co-founder shareholder further strengthens his position by exercising “BSPCE” warrants
-
June 28, 2023 • Results of the combined general meeting of June 27, 2023
-
June 21, 2023 • Approval for its patent to be granted on NFL-101 in Europe and approval of the clinical development plan for NFL-101 by the EMA
-
May 09, 2023 • Recruitment completed for the PRECESTO study
-
April 25, 2023 • 2022 full-year business and earnings update
-
February 27, 2023 • Changes in the governance
-
February 22, 2023 • Inclusion of the first volunteer in the PRECESTO study
-
February 20, 2023 • NFL Biosciences receives €1.7 million in « Avance Innovation » funding from Bpifrance
-
February 02, 2023 • Collaboration with the CEA to study the mechanism of action of its drug candidate NFL-101
-
January 31, 2023 • Very successful capital increase for NFL Biosciences with over €3 million raised
-
January 30, 2023 • NFL Biosciences launches a round of fundraising for approximately 2.5 million euros
-
January 20, 2023 • CESTO II trial progressing on schedule
-
January 17, 2023 • Financial calendar for the first half of 2023
-
January 11, 2023 • NFL Biosciences receives a joint grant from the French Government and the Occitanie Region for its PRECESTO clinical trial
-
November 8, 2022 • Clinical trial approved to demonstrate the complementarity of NFL-101 with other smoking cessation treatments
-
November 2, 2022 • New patent application associating NFL-101 with other smoking cessation treatments
-
October 25, 2022 • 2022 first-half business and earnings
-
October 5, 2022 • NFL Biosciences partners with Themis Medicare for the development of NFL-101 in India
-
June 24, 2022 • NFL Biosciences to present at the H.C.Wainwright 1st annual mental health conference
-
May 25, 2022 • NFL Biosciences, committed to fight against smoking, fully supports World No Tobacco Day on May 31
-
May 11, 2022 • Decision to approve the issuing of its patent in South Korea
-
April 11, 2022 • Notice of allowance of its patent in China
-
March 28, 2022 • 2021 full-year business and earnings update
-
February 2, 2022 • Co-development agreement for a drug candidate to reduce alcohol consumption
-
December 14, 2021 • Phase II/III clinical trial launched for smoking cessation
-
November 17, 2021 • Agreement signed with Diverchim to manufacture its active ingredients
-
October 4, 2021 • 2021 half-year financial and business report
-
September 21, 2021 • Approval for its patent to be granted in the United States
-
September 15, 2021 • Phase II/III clinical trial for NFL-101 for smoking cessation approved in France
-
September 6, 2021 • Analyst coverage launched with Invest Securities
-
July 20, 2021 - Establishment of a liquidity agreement (in French only)
-
June 30, 2021 • Success of the IPO on Euronext Growth Paris
-
June 16, 2021 • NFL Biosciences launches its initial public offering on Euronext Growth Paris (in French only)
-
June 2, 2021 • French smoking cessation innovation approved for Phase II clinical trial (in French only)